We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk

By LabMedica International staff writers
Posted on 04 May 2026

High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. More...

However, most risk assessment begins only after pregnancy has started. Identifying risk earlier could improve how care teams counsel patients and plan preventive strategies. New findings show that routine blood tests performed several years before pregnancy are associated with later risk of hypertension and pre-eclampsia.

Researchers at Karolinska Institutet (Stockholm, Sweden) analyzed pregestational cardiometabolic biomarkers measured during health examinations four to six years before a first pregnancy. The approach evaluates routinely collected indicators—blood sugar, blood lipids, haptoglobin as a marker of low‑grade inflammation, and the TyG index, described as reflecting impaired glucose metabolism—to stratify risk. Associations were assessed using the Stockholm-based AMORIS database and subsequent linkage to national registers.

The cohort comprised just over 35,000 women in Stockholm, Sweden, all expecting their first child. Baseline laboratory values came from health examinations conducted four to six years before conception, and pregnancy outcomes were ascertained from national registers. The investigation is described as an observational study and was published online on April 30, 2026, in JAMA Network Open.

Overall, 5.5% of participants developed high blood pressure or pre‑eclampsia during pregnancy. Depending on which biomarker was elevated, 5.5% to 12.8% of women with pregestational metabolic disturbances were affected, compared with 4.1% to 5.3% among women whose levels were within the normal range. Even moderately elevated levels of LDL cholesterol, triglycerides, apolipoprotein B, haptoglobin, and the TyG index were associated with increased risk.

The researchers note that the causes of pregnancy‑related hypertension are complex and not fully understood. Because the study is observational, the results should be interpreted with caution and do not establish causality. Next steps include evaluating whether early abnormalities in blood sugar, lipids, and inflammation predict other outcomes such as gestational diabetes and preterm birth, and examining links with women’s long‑term cardiovascular health.=

“Our results suggest that the increased risk may begin even at levels currently considered normal. This means that routine blood tests could be used as an additional tool to help healthcare professionals assess risk and discuss lifestyle with women of childbearing age, both before and early in pregnancy,” said Karin Leander, senior lecturer and associate professor at the Institute of Environmental Medicine, Karolinska Institutet.

Related Links
Karolinska Institutet


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.